Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims


     Quick Explanation



    Jane Rogers β€” scientific strength check (evidence-grounded)
    Based strictly on the papers you supplied in the research data (their DOIs below), the strongest evidence for scientific contribution patterns is: (1) large-scale genome project / sequencing infrastructure work in a review setting (likely organizational genomics impact) , (2) mechanistic cell-biology with multi-method validation (proximity labeling + EGFR trafficking/signaling readouts + in vitro biochemistry + compound screening) , and (3) a longitudinal human immunogenomics cohort using RNA-seq + genotype + eQTL/TWAS frameworks with stated data/code access . However, your prompt does not provide author-by-author confirmation that β€œJane Rogers” is an author on every listed paper, so attribution certainty is limited (a major blind spot).


     Long Explanation



    Author Review: Jane Rogers β€” evidence-based, skeptical
    Epistemic note: Your input provides DOI-tagged paper summaries plus some OpenAlex metadata (without DOI for the author-level record). Because you did not explicitly confirm that the listed papers are authored/coauthored by β€œJane Rogers”, this review evaluates the scientific content patterns of the provided papers rather than proving authorship. Where attribution is uncertain, I mark it explicitly.
    1) Visual evidence from your provided raw extracts
    I visualize only the quantitative values explicitly present in your research data excerpts (no invented numbers).
    2) Scientific strength assessment (from the provided paper set)
    2A. Large-scale genomics / sequencing capacity & governance framing (review/memoir)
    The Sanger Centre HGP narrative describes operational scaling (teams/instruments/reads), public-release governance (β€œBermuda Principles”), and milestone outcomes (e.g., finished human genome size and euchromatin fraction) .
    Strength (science perspective): Organizational and technical details can be valuable for understanding what enabled later reproducible reference builds (pipelines, data releases, finishing workflows), which matters when assessing β€œhow science gets done.”
    Limitation (bias): Memoir-style evidence is susceptible to selection and recall bias; it is not a controlled experimental study .
    2B. Mechanistic ubiquitin-ligase activation β†’ tyrosine kinase downregulation (cell + biochemical + screening)
    The CBL activation study (as summarized in your excerpt) uses engineered CBL variants tagged with proximity labeling, LC–MS/MS interactome workflows, and functional assays tracking EGFR phosphorylation/ubiquitination and endocytosis, alongside in vitro ubiquitination assays .
    Strength (science/rigor): Multi-modal mechanistic triangulation (proximity labeling + biochemical activity + downstream signaling and trafficking) increases confidence relative to single-readout papers .
    Skeptical counterpoints: (1) Engineered/overexpression systems can distort stoichiometries and localization. (2) Proximity labeling can reflect closeness without direct binding. (3) Translational relevance is not established in the excerpt because in vivo validation is described as missing .
    2C. Longitudinal puberty immunogenomics (RNA-seq + eQTL + TWAS)
    The puberty/asthma cohort study reports age-associated leukocyte gene expression changes and puberty-stage effects with sex-specific patterns, using differential expression frameworks and eQTL/TWAS analyses; it additionally reports access to phenotype/genotype data on dbGAP and code on GitHub .
    What looks scientifically strong: longitudinal design and integration of genetics (eQTL) + prediction/association (TWAS) can reduce purely observational confounding, and the excerpt’s stated access improves reproducibility prospects .
    What to scrutinize (bias & uncertainty): self-reported puberty staging without direct hormone measures and limitations to an asthma-only pediatric cohort can limit generalizability; also, whole blood leukocyte composition can confound expression unless modeled .
    2D. Comparative genomics depth study (pig assembly depth vs annotation quality)
    The pig SSC17 region analysis evaluates how increased sequencing depth affects contiguity and transcript/annotation quality, including explicit depth-specific outcomes and acknowledgement that lower-depth absence calls may reflect assembly gaps .
    Scientific strongpoint: within-region depth comparison is a clear design for separating β€œmore reads” from other genome-wide differences; the excerpt explicitly provides numeric contig and transcript realignment metrics (which I visualized) .
    2E. Drug resistance genetics framing (ABC transporter haplotypes/SNPs)
    The ABC transporter exon/haplotype study (as excerpted) identifies novel SNPs and linkage disequilibrium patterns in ABC transporter genes, with sample composition spanning controls and epilepsy cohorts .
    Skeptical lens: population stratification and limited demographic diversity can inflate apparent associations; the excerpt explicitly notes possible generalizability constraints .
    2F. Strongest reproducibility & evidence pattern signals (what your set suggests)
    Across these diverse domains (genome projects, mechanistic signaling, immunogenomics, and comparative depth), the strongest β€œscientific quality” indicators are: (i) multi-method triangulation in mechanism work , (ii) explicit quantitative outcomes with acknowledged limitations in technical genomics , (iii) longitudinal design + data/code availability in human omics .
    3) What would most change this review? (falsification targets)
    • Authorship confirmation: If β€œJane Rogers” is not actually a coauthor on several (or all) of the provided papers, the scientific-strength inference to the author should be discounted.
    • Reproducibility: If raw data/code availability is absent for key experiments (especially mechanism and compound screening), confidence should drop (your excerpt for the CBL paper explicitly notes no data availability statement) .
    • Overclaim checks: If downstream effects attributed to CBL activation fail under orthogonal perturbations (e.g., CBL knockout/rescue controls) or show cell-line specificity only, mechanism claims would need revision .


    Feedback:    

    Updated: April 15, 2026

     Top Data Sources ExportMCP



     Analysis Wizard



    It will parse the provided DEGs and pig-depth metrics into clean tables and generate Plotly bar charts for DEG counts and assembly contiguity, ensuring axis labels and units match the excerpt values.



     Hypothesis Graveyard



    That proximity labeling alone proves direct physical binding between RE-CBL and EGFR/EPS15; instead, proximity signals may persist without direct complex formation, so physical binding claims would be premature.


    That sequencing depth effects observed in one pig BAC-derived 8 Mb region universally generalize genome-wide; assembly-gap composition and repeats could make other regions behave differently.

     Science Art


    Author Review: Jane Rogers Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.